BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Whether genetic risk features such as IKZF1 deletions, which are associated with unfavorable outcomes in BCR::ABL1-positive ALL, also play a role in CML-BP and should be considered in therapy stratification has not been investigated [28].